We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: Esophageal Adenocarcinoma
MedXY News
EnglishTag

Esophageal Adenocarcinoma

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Achalasia and Its Differential Impact on Esophageal Squamous Cell Carcinoma and Adenocarcinoma Risk: Insights from a Large Nordic Case-Control Study
GastroenterologyepidemiologyEsophageal Adenocarcinoma

Achalasia and Its Differential Impact on Esophageal Squamous Cell Carcinoma and Adenocarcinoma Risk: Insights from a Large Nordic Case-Control Study

By MedXY|Sep 5, 2026

A comprehensive multinational study reveals that achalasia significantly raises the risk of esophageal squamous cell carcinoma independently, while its association with adenocarcinoma is modest and largely mediated by gastroesophageal reflu

Comparing FLOT and CROSS Protocols: Survival and Recurrence in Esophageal Adenocarcinoma with Pathological Complete Response
Gastroenterology
CROSS chemoradiotherapy
Esophageal Adenocarcinoma

Comparing FLOT and CROSS Protocols: Survival and Recurrence in Esophageal Adenocarcinoma with Pathological Complete Response

By MedXY|Jul 24, 2026

This cohort study compares long-term survival and recurrence in esophageal adenocarcinoma patients achieving pathological complete response (pCR) after neoadjuvant FLOT chemotherapy versus CROSS chemoradiotherapy, highlighting better outcom

Therapeutic Reversal of SOX9-Mediated Chemoresistance in Esophageal Adenocarcinoma via APE1-Redox Inhibition
Clinical UpdatesAPE1Chemoresistance

Therapeutic Reversal of SOX9-Mediated Chemoresistance in Esophageal Adenocarcinoma via APE1-Redox Inhibition

By MedXY|Mar 15, 2026

This review details a breakthrough in esophageal adenocarcinoma treatment, identifying the APE1-SOX9 axis as a primary driver of chemoresistance and demonstrating how targeting APE1’s redox function can sensitize tumors to oxaliplatin

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities